
    
      Objective of this pivotal study was to assess the bioequivalence between Test Product:
      Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India and the corresponding
      Reference Product: CoregÂ® (Carvedilol Tablets) 12.5 mg Tablets of M/s GlaxoSmithKline, under
      fasting condition in normal, healthy, adult, human subjects in a randomized crossover study.

      The study was conducted with 42 healthy adult subjects. In each study period, a single 12.5
      mg dose of either test or reference was administered to the subjects as per the randomization
      schedule in each study period with about 240 mL of water at ambient temperature in sitting
      position.

      The duration of the clinical phase was approximately 11 days including washout period of at
      least 7 days between administrations of study drug in each study period.
    
  